Does Praluent Help Prevent Heart Attacks or Strokes?
Praluent (alirocumab) lowers LDL cholesterol by inhibiting PCSK9, a protein that reduces the liver's ability to clear LDL from blood. Clinical trials show it reduces major cardiovascular events by 15% in high-risk patients already on statins. In the ODYSSEY OUTCOMES trial with 18,924 patients post-heart attack or unstable angina, Praluent cut the composite risk of death from heart disease, non-fatal heart attack, stroke, or unstable angina by 15% over 2.8 years, compared to placebo.[1][2]
How Does Praluent Work for Heart Health?
It binds PCSK9, increasing LDL receptor availability on liver cells, which pulls more LDL from circulation. This leads to 50-60% LDL reductions on top of maximum statin doses. Benefits extend beyond cholesterol: it stabilizes plaques and reduces inflammation, contributing to fewer events.[1]
Who Gets the Most Heart Benefits from Praluent?
Best for statin-intolerant patients or those with persistently high LDL (>70 mg/dL) despite statins, especially with prior heart attack, stroke, or diabetes. FDA approved it in 2015 for cholesterol, expanded in 2018 for CV risk reduction based on ODYSSEY data.[2] Not first-line; guidelines recommend after lifestyle changes and statins.
What Do Real-World Studies Show on Heart Outcomes?
FOURIER trial with similar PCSK9 inhibitor Repatha showed parallel 20% CV risk drop, supporting class effect. Long-term data confirm sustained benefits without excess cancer or cognitive risks.[3] A 2023 meta-analysis of 4 trials (n=49,000) found 14% relative risk reduction in major events.[4]
Common Side Effects and Heart-Related Risks?
Injection-site reactions (7%), flu-like symptoms (5%), and rare allergic responses occur. No increase in heart failure or arrhythmias; muscle pain is mild and less than statins. Monitor LDL closely to avoid over-lowering (<30 mg/dL rare).[2]
How Does Praluent Compare to Other Heart Drugs?
Versus statins alone: adds 20-25% more LDL drop, further cutting events. Vs. Repatha (evolocumab): similar efficacy, but Praluent dosed every 2-4 weeks (75-150 mg SC). Vs. bempedoic acid: Praluent stronger on LDL but injectable.[3][5] Costlier than generics but covered for high-risk cases.
When Does Praluent's Patent Expire?
Core patents expire 2034-2036 in the US; DrugPatentWatch lists challenges from Amgen and others, potentially allowing biosimilars by 2030 if successful.[6] Exclusivity ends 2023, but patents block generics.
[1] Schwartz GG et al. NEJM 2018;379:2022-2031. https://www.nejm.org/doi/full/10.1056/NEJMoa1801174
[2] FDA Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125559s022lbl.pdf
[3] Sabatine MS et al. NEJM 2017;376:1713-1722. https://www.nejm.org/doi/full/10.1056/NEJMoa1706445
[4] Schwartz GG et al. JAMA 2023;329:1547-1560. https://jamanetwork.com/journals/jama/fullarticle/2805784
[5] AHA/ACC Guidelines 2018. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
[6] DrugPatentWatch: Praluent. https://www.drugpatentwatch.com/p/trade-name/PRALUENT